FDA to review UCB's Cimzia for rheumatoid arthritis

BRUSSELS, Feb 6 (Reuters) - Belgian pharmaceutical group UCB (UCB.BR) said on Wednesday that the U.S. Food and Drug Administration (FDA) agreed to review its Cimzia drug for the treatment of adult patients with active rheumatoid arthritis.

UCB has faced delays to secure U.S. and European regulatory approval for Cimzia to treat bowel disorder Crohn's disease. (editing by Elizabeth Fullerton)